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Big pharma is increasingly looking to academia for new drug leads and technologies; 
meanwhile universities are being forced to look beyond the National Institutes of Health 
(NIH) for funding. This mutual attraction-out-of-necessity is helping to forge new bonds 
between industry and academia.The notion of a blockbuster drug 
that generates more than $1 billion 
in revenue a year for a big pharma 
company is waning. Both the busi-
ness model that produces these 
monster money-makers as well as 
the technology underlying drug R&D 
appear to be positioned to make 
blockbusters a by-product rather 
than a goal of a changing system. 
“Pharma is not depending on the 
blockbuster, they moved away from 
that strategy,” says Kenneth Kaitin, 
director of the Tufts Center for the 
Study of Drug Development in Bos-
ton. In addition to the expense of 
developing drugs with broad indi-
cations for large patient popula-
tions, the same type of drugs tend 
to hit the marketplace at the same 
time, creating a horse race between 
companies that escalates market-
ing costs, says Kaitin. And against 
the odds, if a drug does become a 
blockbuster, “the company becomes 
in an unhealthy way reliant upon 
that product,” he says. Additionally, 
“when the drug goes off patent, the 
company suffers.” Points out Simon 
Goodall, leader of Boston Consult-
ing Group’s (BCG) biopharmaceuti-
cal R&D practice, “Obviously, if you 
can I.D. and develop a blockbuster, 
it’s still valuable for a portfolio... But 
the business model itself is break-
ing down. Nobody has the answer 
yet. You can’t point to a company 
that has the new business model.”
The pressure to change business 
models is also being driven by what 
lies ahead: loss of patent protec-
tion for some notable blockbusters 
following the examples of Zoloft 
(Pfizer) and Pravachol (Bristol-Myers 
Squibb) and potentially fewer new 
molecular entities or NMEs—mol-
ecules containing no active moiety with physiological/pharmacological 
action that is already approved by 
the US Food and Drug Administration 
(FDA). Indeed, between 2002 and 
2005 there were 87 NMEs approved 
by the FDA, compared to 116 from 
1998–2001 and 142 from 1994–1997. 
Almost $40 billion in revenue for the 
top pharmaceutical companies is at 
risk due to patent expiration in 2010 
alone, according to BCG. And for 
the period 2011–2015, the dollar loss 
due to patent expiration is estimated 
at ~$28 billion annually.
In the past, big pharma would 
have turned to biotech to pump up 
its slowing pipeline of new drugs. 
It is still doing so, but the pickings 
are getting slim as companies with 
promising therapeutics and tech-
nologies get spoken for. This is a 
“problem, as more companies are 
bidding for fewer and fewer assets 
in biotech, it’s not sustainable,” 
says Robert Ruffolo, president of 
R&D for Wyeth Pharmaceuticals 
in Collegeville, PA. “Big pharma is 
paying lots of money, and it can’t 
fill a pipeline by doing so, it’s too 
expensive.”
At the same time, biotech itself is 
changing. “Biotech in the 90s was 
the middleman,” says James Wells, 
director of the small molecule dis-
covery center at the University of 
California, San Francisco (UCSF). 
“But the middlemen have gone away. 
Middlemen became pharma, it’s 
now bio-pharma. Biotech is so prod-
uct-driven right now. Now compa-
nies pitch to investors about devel-
opment-specific assets: develop 
for two years, sell and it’s over. It’s 
almost like the business model in 
motion pictures, you create this little 
company for two years, you create a 
picture, it’s out and it disbands.”Cell 12Wells, formerly a senior scien-
tist at Genentech and president of 
Sunesis Pharmaceuticals, doesn’t 
necessarily think this is bad for bio-
tech. “The market will tell,” he says. 
“Maybe nothing is wrong with that, 
though [it opens] an early-technol-
ogy void.” To fill that void, both big 
pharma and biotech are looking 
more intensely to academia. “There 
is competition between biotech and 
pharma for university technology,” 
says Paul Pospisil, a managing 
partner in Aduro Capital, a venture 
capital firm in New York City. Bio-
tech has always gone to academia 
for technology and drug leads, says 
Pospisil, but what has shifted now 
is that “pharma is willing to take 
on academic research earlier than 
it would have maybe 15 years ago, 
when it would take up where biology 
was already well established.”
Buried Patent Treasure
Between 2000 and 2005, univer-
sity and institution invention dis-
closures by respondents to a US 
licensing survey increased steadily 
from ?12,000 to more than 17,000, 
according to the Association of 
University Technology Managers 
(http://www.autm.net/pdfs/AUTM_
LS_05_US.pdf). New patents filed 
also rose from ?6,000 in 2000 to 
?10,000 in 2005.
“There’s a lot of insight left on 
the table at academic labs” with 
the potential for contributing to 
new drug leads or technology, says 
Merv Turner, senior vice president 
for worldwide licensing and external 
research at Merck. Since 2000, the 
public markets have ceased to be 
an exit strategy for biotech compa-
nies, so they are looking to mergers 
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cal companies to build equity value, 
Turner says, and as a result venture 
capitalists are no longer focusing 
their funds on early-stage drug dis-
covery. “So for academic research-
ers it is harder to see their innova-
tions reach development.”
To tap into this trend, Merck 
is developing a system of scouts 
based in Boston, San Diego, Japan, 
and the UK. “Five years ago my job 
didn’t exist,” says Reid J. Leonard, 
a scout and executive director for 
licensing and external research at 
Merck Research Laboratories in 
Boston. “We are looking for oppor-
tunity extensions of our science out-
reach for licensing, organized around 
geography rather than therapeutic 
area. What I do is very similar to what 
a person with my background would 
do in a venture capital firm. I really 
am the first part of engagement on 
novel opportunity.”
Leonard says that they have 
concentrated their outreach on 
licensing and will be expanding to 
a systemic approach working with 
academic scientists on biomarkers, 
target identification and validation, 
and methodologies for carrying out 
proof-of-concept studies. Merck, 
of course, is not alone in their out-
reach efforts. Novartis, Pfizer, and 
Amgen have also set up a presence 
in the Boston area, an ideal location 
because of its proximity to leading 
universities and medical centers.
The interest works both ways, 
especially as NIH funding has 
remained relatively flat since 2003—
the fiscal year 2007 NIH budget is 
estimated at $29.2 billion versus 
$27.2 billion in 2003 (http://www.
aaas.org /spp/rd /health08p.pdf ) . 
When inflation is factored in, this 
actually represents a 16% decrease, 
according to an analysis in the May 
2007 Journal of the American Medi-
cal Association (JAMA 297,1867).
“Academic labs flailing along are 
looking to how they can move a 
little further downstream to make 
themselves more attractive to com-
panies,” says Karen Bernstein, edi-
tor-in-chief of the biotechnology 
industry newsletter BioCentury 
based in Belmont, CA. Is it through 848 Cell 129, June 1, 2007 ©2007 Elsevi“more animal models? More chem-
istry to present the commercial 
world with a more fully developed 
molecule? The answer is not in yet.” 
Traditionally university tech trans-
fer offices push technology toward 
industry, but the challenge remains 
to fund post-NIH but precommer-
cial research in the first place, says 
Isaac T. Kohlberg, chief technol-
ogy development officer at Harvard 
University. “How do you bridge this 
gap so the technology doesn’t wind 
up in death valley?” As big pharma 
moves toward academia, universi-
ties are also reaching out.
Academia’s Creative Solutions
One strategy is Harvard’s Accelera-
tor Fund, which seeks to raise $15 
million to allocate to translational 
research. To date about $5 million 
has been raised, says Kohlberg, 
and approximately $1.25 million is 
expected to be distributed to five or 
six projects this year. The funds are 
raised from philanthropic sources 
as gifts, says Larry Schlossman, a 
director at Harvard’s office of tech-
nology development. Examples of 
projects eligible for funding include 
the design and synthesis of small-
molecule inhibitors of drug targets, 
testing of monoclonal antibodies, 
testing of lead small molecules 
in animal models of disease, and 
medicinal chemistry followup of hits 
from drug target screening assays 
(http://www.techaccelerator.har-
vard.edu/guidelines.php). Final 
selection will be made by a commit-
tee of venture capitalists, industry 
executives, and Harvard faculty, 
says Schlossman.
At Stanford, researchers are tak-
ing matters into their own hands and 
looking for orphan technologies that 
sit in the tech transfer office but have 
yet to be claimed by a company. The 
technologies selected get one year 
of funding from the university and, 
perhaps as importantly, says pro-
gram founder Daria Mochly-Rosen, 
mentoring by faculty with company 
experience.
Mochly-Rosen, a professor in the 
department of chemical and sys-
tems biology at Stanford University er Inc.School of Medicine, started this so-
called SPARK program out of frus-
tration with trying to get companies 
interested in her protein kinase C 
research. “Protein kinase C showed 
it can limit damage to the heart 
after a heart attack,” says Mochly-
Rosen. “I thought Stanford was 
doing a poor job in finding a part-
ner, so I tried. And I found Stanford 
was doing a good job and industry 
wasn’t interested. It didn’t see a 
kinase as a drug.”
She ended up founding her own 
company, KAI Pharmaceuticals, 
where she worked for a year. Upon 
returning to Stanford, she wanted to 
use her newfound industry insight 
to help fellow academic research-
ers. If a new drug target or technol-
ogy “doesn’t look like, smell like, 
or walk like a duck,” then indus-
try is reluctant to develop it, says 
Mochly-Rosen. So the goal was to 
pick promising but neglected tech-
nologies and work with the investi-
gators to give them more company 
appeal. Mochly-Rosen asked peo-
ple from industry to whittle down 
approximately 470 unlicensed pat-
ents from Stanford’s office of tech-
nology licensing to 40, and then six. 
She called the investigators. “We 
didn’t expect faculty [to work on the 
technology], only post docs, but we 
were surprised, there is faculty, too, 
on every project.”
SPARK projects include a hepa-
titis C treatment, antiaging drug 
discovery, protease-based diag-
nostics and therapeutics, diagnos-
tics for kidney transplant rejection 
and pancreatitis, and targeting of 
the unfolded protein response for 
treating cancer. Mochly-Rosen 
calls SPARK an experiment, and the 
odds against a company picking up 
one or more of the six projects are 
very high. But “via teaching crite-
ria, we are already successful,” she 
says. “As a university, we teach a 
lot of scientists to be academicians 
but many of our students wind up 
in industry and we don’t train them. 
People are leaving [SPARK] with 
what they hadn’t learned before.” 
One example is a drug package 
insert that accompanies prescrip-
tion medication and offers pharma-
cological and clinical information, 
which Mochly-Rosen asked the 
researchers to write. “It made them 
realize that industry is working from 
the end. This is very different than 
the academia hypothesis-driven” 
approach, she says.
Craig Garner, a developmental 
neurobiologist at Stanford, was 
approached by Mochly-Rosen. His 
research focuses on manipulating 
inhibition associated with the neu-
rotransmitter GABA as a cognitive 
treatment for Down’s syndrome. 
“Over a year ago, we wrote a use 
patent and sent it out to more than 
150 companies. One said it was 
interested but wanted even more 
basic information; they liked the 
idea but wanted to decrease risk.” 
SPARK mentors reviewed his mate-
rial and worked with him to posi-
tion it for industry. “The faculty are 
not really aware of what biotech 
wants,” says Garner. As a result, the 
research is “seldom placed in a for-
mat to allow [industry] to say ahh, 
this is one for me.” The patent had a 
“first exposure through the office of 
technology licensing, and this was 
not in a way the community saw 
was important,” he says. SPARK, 
as well as subsequent publication 
and media coverage, broadened the 
exposure, and six additional com-
panies expressed interest.
Other programs designed to 
connect academia more closely 
with industry include those at The 
Scripps Research Institute in La 
Jolla, CA and the J. David Gladstone 
Institutes in San Francisco, both of 
which have made exclusive licensing 
deals with pharmaceutical compa-
nies, says UCSF’s James Wells. The 
Gladstone, for example, has a col-
laboration and licensing agreement 
with Merck for the research and 
development of drugs to treat neu-
rodegenerative diseases, such as 
Alzheimer’s disease, that are linked 
to ApoE-associated mechanisms. 
Merck receives worldwide exclusive 
license to research, develop, and 
commercialize compounds resulting 
from the collaboration; Gladstone 
receives a $3.25 million upfront pay-ment, milestone fees, as well as an 
annual licensing fee and royalties 
on any marketed product stemming 
from the agreement.
Wells also points to the Broad 
Institute in Cambridge, MA, a col-
laboration between MIT and Har-
vard, as adopting some lessons 
from industry to apply genomic 
research to medical problems. “In a 
way, [the Broad is] set up like minip-
harma,” says Wells. “They have 
functional departments like an aca-
demic institution but are matrixed 
around project areas and grants 
like pharma.” BCG’s Simon Goodall 
points to the Myelin Repair Foun-
dation in Saratoga, CA as another 
research model merging indus-
try and academic approaches to 
move basic research from the lab 
to the clinic, in this case focusing 
on treatments for multiple sclero-
sis. The nonprofit foundation pools 
the research efforts of scientists 
from Stanford, McGill, Case West-
ern Reserve, Northwestern, and the 
University of Chicago while aggres-
sively managing the intellectual 
property to apply for patents and 
engage in early discussions with 
pharmaceutical companies with 
the goal of accelerating discoveries 
toward the clinic.
Technology Creates Suitors
Technology itself is also forcing 
academic and private for-profit labs 
into relationships.
“We used to be able to bring new 
technology into our own labs—clon-
ing and genetic manipulation,” for 
example, says Joan Brugge, profes-
sor and chair of the department of cell 
biology at Harvard Medical School. 
“But now it is so advanced: imag-
ing and microscopy and engineer-
ing approaches” that collaborations 
need to move beyond traditionally 
associated groups. “The interactions 
[with companies] were much more 
service-oriented” ten years ago, adds 
Brugge. “Now interactions are [more] 
about discovery… [and] a dynamic 
exchange of ideas.”
Kenneth Kaitin at Tufts points out 
that genomics and personalized med-
icine are also pushing organizations Cell 1together. One example is The RNAi 
Consortium (TRC), a public-private 
partnership formed in 2005 by the 
Broad Institute and including compa-
nies such as Bristol-Myers Squibb, Eli 
Lilly, and Novartis. TRC aims to cre-
ate a shared library of small hairpin 
RNAs to target 15,000 human genes 
and 15,000 mouse genes. This ambi-
tious 3-year plan costing $18 million 
is partly financed by contributions of 
$3.6 million from company member 
organizations (http://www.broad.mit.
edu/genome_bio/trc/). “The move in 
industry is away from broad-based 
indications to stratified medicine. 
To do so, [industry] needs access 
to technology traditionally not avail-
able” to them, says Kaitin. “Much of 
it is going on in government and aca-
demic labs, so it is critical for industry 
to get in there.”
Another example is the public-private 
Biomarkers Consortium (http://www.
fnih.org/Biomarkers%20Consortium/
Biomarkers_home.shtml), backed by 
the NIH, The Foundation for the 
NIH, the FDA, and the Pharmaceuti-
cal Research and Manufacturers of 
America (PhRMA). The partnership 
includes many of the world’s larg-
est pharmaceutical companies and 
is based on the sharing of data and 
intellectual property in order to iden-
tify and validate biomarker tools and 
discoveries in areas including cancer, 
neuroscience, and metabolism. “The 
science is driving us to less of a whole 
population approach and more [of a] 
niche approach,” as exemplified by the 
humanized monoclonal antibody Her-
ceptin, says Marie Vodicka, PhRMA’s 
assistant vice president for biologics 
and biotechnology in Washington, DC. 
“Companies have to keep up with the 
advances in science. The science will 
dictate the drugs. Pharma is evolving.”
An Opportunity for Crosspollination
Although people in industry and 
academia acknowledge this mutual 
need and talk up its benefits, others 
are not entirely convinced. “The offi-
cial lie is people like collaborations, 
but really if you see a collaboration, 
it is success by necessity,” says 
Paul Pospisil. It is “an alignment of 
different interests.” It may even be 29, June 1, 2007 ©2007 Elsevier Inc. 849
an opportunity to poach talent. “The 
relationship between big pharma, 
biotech and academia is that they 
are all competing for the best peo-
ple,” says Charlene Ledbetter of 
LedbetterStevens, a life sciences 
executive search firm in New York 
City. “They are out-and-out com-
petitors” for talent, with academia 850 Cell 129, June 1, 2007 ©2007 Elsevieluring people with cutting-edge 
tools, biotech with equity, and big 
pharma with relative job security, 
she says.
But partnerships may also enhance 
productivity of members of different 
teams. “To get people to be broader 
and innovate is to get them out of 
their setting,” says Ginger L. Gregory, r Inc.global head of human resources for 
Novartis Institutes for BioMedical 
Research in Cambridge, MA. It offers 
them the chance “to get out of their 
therapeutic setting, magnified by 
getting them out of industry into an 
academic lab” and vice versa, says 
Gregory, allowing crosspollination in 
both spheres.
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